Press releasePRNewswire
Brainstorm Cell Therapeutics
BCLI · NASDAQ
$0.80+$0.03 (+3.90%)TodayMarket closed ·
Prev close $0.77
Latest news
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- News
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
- Press releasePRNewswire
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
- News
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director
- Press releasePRNewswire
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
- Press releasePRNewswire
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
- Press releasePRNewswire
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseBusiness Wire
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
- News
A Peek at Brainstorm Cell's Future Earnings
- Press releasePRNewswire
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
- NewsMohd Haider
Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
- Press releasePRNewswire
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
- Press releasePRNewswire
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®
- Press releasePRNewswire
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
Market-Moving News for May 19th
- Press releasePRNewswire
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
- Press releasePRNewswire
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Press releasePRNewswire
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
- News
Earnings Scheduled For May 15, 2025
- Press releasePRNewswire
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
- Press releasePRNewswire
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
Earnings Scheduled For March 31, 2025
- News
A Preview Of Brainstorm Cell's Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.